-- Conference Call Scheduled for Thursday, February 29, 2024, at 8:00 a.m. ET --
NEWTON,
Mass., Feb. 22, 2024 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced it will
report fourth quarter and full year 2023 financial results on
Thursday, February 29, 2024.
Karyopharm's management team will host a conference call and audio
webcast at 8:00 a.m. ET on Thursday,
February 29, 2024, to discuss the financial results and
other company updates.
To access the conference call, please dial (800) 836-8184
(local) or (646) 357-8785 (international) at least 10 minutes prior
to the start time and ask to be joined into the Karyopharm
Therapeutics call. A live audio webcast of the call, along with
accompanying slides, will be available under "Events &
Presentations" in the Investor section of the Company's website,
http://investors.karyopharm.com/events-presentations. An archived
webcast will be available on the Company's website approximately
two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company pioneering novel cancer
therapies. Since its founding, Karyopharm has been an industry
leader in oral Selective Inhibitor of Nuclear Export (SINE)
compound technology, which was developed to address a fundamental
mechanism of oncogenesis: nuclear export dysregulation.
Karyopharm's lead SINE compound and first-in-class, oral exportin 1
(XPO1) inhibitor, XPOVIO® (selinexor), is approved in
the U.S. and marketed by the Company in three oncology indications
and has received regulatory approvals in various indications in a
growing number of ex-U.S. territories and countries, including
Europe and the United Kingdom (as NEXPOVIO®) and
China. Karyopharm has a focused
pipeline targeting multiple high unmet need cancer indications,
including in multiple myeloma, endometrial cancer, myelodysplastic
neoplasms and myelofibrosis. For more information about our people,
science and pipeline, please visit www.karyopharm.com, and follow
us on Twitter at @Karyopharm and LinkedIn.
XPOVIO® and NEXPOVIO® are registered
trademarks of Karyopharm Therapeutics Inc. Any other trademarks
referred to in this release are the property of their respective
owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-29-2024-302068088.html
SOURCE Karyopharm Therapeutics Inc.